Author： Parker Terri Barbarotta Lisa Foss Francine
Publisher： Future Medicine
ISSN： 1479-6694
Source： Future Oncology, Vol.9, Iss.1, 2013-01, pp. : 21-29
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Pralatrexate is a folate analogue metabolic inhibitor manufactured by Allos Therapeutics, Inc., a wholly-owned subsidiary of Spectrum Pharmaceuticals, Inc. In both preclinical and clinical studies, pralatrexate demonstrated activity in lymphoma. Pralatrexate was US FDA approved for the treatment of relapsed/refractory peripheral T-cell lymphoma in 2009. Approval was based on data from the PROPEL trial that demonstrated an overall response rate of 29% in a heavily pretreated patient population. The dose and schedule of pralatrexate is 30-mg/m2 weekly for 6 weeks, given in 7-week cycles. Folate and vitamin B12 supplementation are required to minimize toxicity. The most common toxicities are mucositis, thrombocytopenia, nausea and fatigue.
Related content
Access to resources
Recommend
Iodine 131 tositumomab in the treatment of non-Hodgkin’’s lymphoma
By Smith Stephen Sweetenham John W
Future Oncology, Vol. 3, Iss. 3, 2007-06 ,pp. :
By Morales La Madrid Andres Campbell Nicholas Smith Sonali Cohn Susan Salgia Ravi
Targeted Oncology, Vol. 8, Iss. 4, 2013-12 ,pp. :
By DiJoseph John Dougher Maureen Armellino Douglas Kalyandrug Lyka Kunz Arthur Boghaert Erwin Hamann Philip Damle Nitin
Cancer Immunology, Immunotherapy, Vol. 56, Iss. 7, 2007-07 ,pp. :
By Schütt P. Zimmermann K. Derks C. Ebeling P. Welt A. Poser M. Hense J. Metz K. Anhuf J. Sandmann M. Neise M. Moritz T. Stuschke M. Niederle N. Seeber S. Nowrousian Mohammad
Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. :